A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumors.

In 30 seconds

This phase 1, open-label, dose-escalation trial assessed the safety and pharmacokinetics of acasunlimab, both alone and in combination with pembrolizumab, in Japanese patients with advanced or metastatic solid tumors. The study found that grade 3 treatment-related adverse events occurred in 5 of 15 patients receiving acasunlimab monotherapy, indicating a manageable safety profile.

Key findings

• Grade 3 treatment-related adverse events occurred in 5 of 15 patients receiving acasunlimab monotherapy.
• One of three patients receiving acasunlimab plus pembrolizumab experienced a grade 3 treatment-related adverse event.
• No dose-limiting toxicities or treatment-related adverse events leading to death were reported.
• Six patients on acasunlimab monotherapy and one on combination therapy achieved stable disease.

Why it matters

Understanding the safety and pharmacokinetics of new therapies like acasunlimab is crucial for clinicians managing advanced solid tumors, as it informs treatment decisions and patient monitoring.